- Home
- NTRB vs GNTA Comparison
NTRB vs GNTA Comparison
Compare NTRB & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTRB | GNTA |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.7M | 34.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NTRB | GNTA |
|---|---|---|
| Price | $4.69 | $1.44 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | 19.6K | ★ 92.8K |
| Earning Date | 12-11-2025 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,278,321.00 | N/A |
| Revenue This Year | $30.17 | N/A |
| Revenue Next Year | $3,394.36 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.69 | N/A |
| 52 Week Low | $3.72 | $1.28 |
| 52 Week High | $11.78 | $10.00 |
Technical Indicators
Market Signals| Indicator | NTRB | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 45.40 | 36.07 |
| Support Level | $4.34 | $1.28 |
| Resistance Level | $4.77 | $1.68 |
| Average True Range (ATR) | 0.37 | 0.17 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 38.63 | 27.42 |
Price Performance
Historical ComparisonAbout NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.